stockrowRoyalty Pharma PLC
RPRX Healthcare Biotechnology
Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.
- Revenue
- +13.3%
- EPS
- −51.5%
- Free cash flow
- +364.6%
- Total debt
- −4.00%
Quarter to September 2026, against a year earlier
Follow RPRX
Alert me
Royalty Pharma PLC (RPRX) Operating cash flow
Royalty Pharma PLC's operating cash flow for fiscal 2025 was $2.5B, down 10.1% from $2.8B in fiscal 2024. Over the twelve months to 30 September 2026 it was $3.0B. Over the past ten years it has ranged from $1.6B (fiscal 2018) to $3.0B (fiscal 2023); the current reading is higher than 75% of that period. Royalty Pharma PLC ranks 3rd of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $2.5B | (10.08%) |
| FY2024 | $2.8B | (7.32%) |
| FY2023 | $3.0B | 39.36% |
| FY2022 | $2.1B | 6.27% |
| FY2021 | $2.0B | (0.84%) |
| FY2020 | $2.0B | 22.04% |
| FY2019 | $1.7B | 3.02% |
| FY2018 | $1.6B | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $686.1M | (5.82%) |
| Jun 2026 | $728.5M | 1.42% |
| Mar 2026 | $718.2M | (13.17%) |
| Dec 2025 | $827.1M | 17.72% |
| 27 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| RPRX Royalty Pharma PLC | $3.0B |
| ARGX argenex SE compare | $1.6B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $1.6B |
| GMAB Genmab A/S Sponsored ADR compare | $891.0M |
| INCY Incyte Corporation compare | $745.0M |
| BNTX BioNTech SE Sponsored ADR compare | −$277.2M |
| INSM Insmed, Inc. compare | −$595.6M |
| ROIV Roivant Sciences Ltd. compare | −$816.5M |
| RVMD Revolution Medicines, Inc. compare | −$1.4B |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on RPRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement